Evidence map›Paper›PMID 34260734›Full record

ReviewThe Journal of clinical endocrinology and metabolism2021

Approach to the Patient With Adrenal Incidentaloma.

Irina Bancos, Alessandro Prete

2 registry-linked trialsOpen access · greenAbstract readCase ReportsReview
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 108 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 3 pooled it
22.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07361874 narecruitingnot on this mapstarted 2026, after this paper: background citation

IMPACT-MACS Study: Investigating the Mechanisms, Pathophysiology, and Cardiometabolic Treatment in Mild Autonomous Cortisol Secretion

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2026 to 2030Enrolled75ConditionsMild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol ExcessArmsIntervention 1: Adrenalectomy, Intervention 2: Semaglutide
NCT07573163 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

TypeinterventionalSponsorAlaa SadaRan2026 to 2028Enrolled34ConditionsMild Autonomous Cortisol Secretion (MACS), Adrenalectomy, StatusArmsTirzepatide, Standard medical treatment
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 168 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Irina BancosDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9332-2524
Alessandro PreteInstitute of Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK.ORCID 0000-0002-4821-0336
Mayo Clinic · USUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Skeletal Consequences of Mild Autonomous Cortisol SecretionK23DK121888 · NIDDK · MAYO CLINIC ROCHESTER · PI BANCOS, IRINA · 2019 to 2022
$630k
NIDDK NIH HHS K23 DK121888NIH HHS K23DK121888
6 · The paper itself

Abstract

Adrenal tumors are commonly discovered incidentally on cross-sectional abdominal imaging performed for reasons other than adrenal mass. Incidence of adrenal tumors increased 10-fold in the past 2 decades, with most diagnosed in older adults. In any patient with a newly discovered adrenal mass, determining whether the adrenal mass is malignant and whether it is hormonally active is equally important to guide the best management. Malignancy is diagnosed in 5% to 8% of patients with adrenal tumors, with a higher risk in young patients, if history of extra-adrenal malignancy, in those with large adrenal tumors with indeterminate imaging characteristics, and in bilateral adrenal tumors. Although overt hormone excess is uncommon in adrenal incidentalomas, mild autonomous cortisol secretion can be diagnosed in up to 30% to 50% of patients. Because autonomous cortisol secretion is associated with increased cardiovascular morbidity and metabolic abnormalities, all patients with adrenal incidentalomas require work up with dexamethasone suppression test. Management of adrenal tumors varies based on etiology, associated comorbidities, and patient's preference. This article reviews the current evidence on the diagnosis and evaluation of patients with adrenal mass and focuses on management of the most common etiologies of adrenal incidentalomas.

Indexed as

Incidental FindingsAdrenal Gland NeoplasmsAdultFemaleHumansHydrocortisoneMaleMiddle AgedPrognosisUnited KingdomYoung AdultHydrocortisoneadrenal massdexamethasone suppression testdiagnosishormonal work upHounsfield unitsimagingmalignancy

Identifiers

PMID34260734
PMCPMC8530736
OpenAlexW3179348892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.